Studies over the past decade aimed at delineating the molecular mechanisms involved in SSc fibrosis have identified TGF-β as a central player and the TGF-β signaling pathway as an important target for therapeutic intervention for SSc [2,5,14]. This evidence concerns the gene TGFB1 and systemic sclerosis.